Atara Biotherapeutics, Inc. – LSE:0HIY.L

Add to watchlist

$15.886

+3.61

+29.47%

Market closed

Open in 1 day

+21.25%

month

+21.25%

quarter

+2091.07%

year

Market Cap	76.15M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.13

Revenue	34.70M
EBITDA	-212.91M
Income	-233.10M
Revenue Q/Q	2131.40%
Revenue Y/Y	-39.62%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-613.52%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Atara Biotherapeutics, Inc. (LSE:0HIY.L): Profit margin
Jun 2023	957K	-71.10M	-7430.3%
Sep 2023	2.13M	-69.79M	-3264.59%
Dec 2023	4.25M	-60.45M	-1421.68%
Mar 2024	27.35M	-31.75M	-116.07%

Atara Biotherapeutics Financials Estimate

Q Y

Atara Biotherapeutics, Inc. (LSE:0HIY.L): Analyst Estimates
Dec 2023	4.25M	-60.45M	-1421.68%
Mar 2024	27.35M	-31.75M	-116.07%
Oct 2025	11.4M	-36.55M	-320.64%
Dec 2025	12.8M	-35.14M	-274.58%

Analysts Price target
Financials & Ratios estimates

Atara Biotherapeutics, Inc. (LSE:0HIY.L): Debt to assets
Jun 2023	246439000	238.98M	96.98%
Sep 2023	188788000	239.62M	126.93%
Dec 2023	165504000	264.73M	159.96%
Mar 2024	165272000	263.57M	159.48%

Atara Biotherapeutics, Inc. (LSE:0HIY.L): Cash Flow
Jun 2023	-52.79M	49.48M	471K
Sep 2023	-51.34M	70.44M	-208K
Dec 2023	-50.40M	9.94M	1.51M
Mar 2024	-29.61M	14.71M	24.14M

Atara Biotherapeutics alternative data

Atara Biotherapeutics
Employees

Atara Biotherapeutics, Inc. (LSE:0HIY.L): Employee count
Aug 2023	330
Sep 2023	317
Oct 2023	317
Nov 2023	317
Dec 2023	334
Jan 2024	334
Feb 2024	334
Mar 2024	334
Apr 2024	334
May 2024	225
Jun 2024	173
Jul 2024	173

Status	Patent	Filling date	Issue date
Application	Application METHODS OF MANAGING TUMOR FLARE IN ADOPTIVE IMMUNOTHERAPY Filling date: 22 Oct 2018 Issue date: 23 Dec 2021	22 Oct 2018	23 Dec 2021
Application	Application METHODS FOR EXPANDING ANTIGEN-SPECIFIC CAR-T CELLS, COMPOSITIONS AND USES RELATED THERETO Filling date: 10 Sep 2019 Issue date: 30 Sep 2021	10 Sep 2019	30 Sep 2021
Application	Application SYSTEMS AND METHODS FOR DISTRIBUTING CELL THERAPIES Filling date: 7 Jan 2019 Issue date: 5 Nov 2020	7 Jan 2019	5 Nov 2020
Application	Application IMMUNOTHERAPY FOR POLYOMAVIRUSES Filling date: 8 Sep 2017 Issue date: 25 Jun 2020	8 Sep 2017	25 Jun 2020
Application	Application METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS Filling date: 19 Jan 2018 Issue date: 21 Nov 2019	19 Jan 2018	21 Nov 2019

Atara Biotherapeutics
Executives

Insider	Age	Compensation
Dr. Pascal Touchon D.V.M. (1963) Pres, Chief Executive Officer & Director	62	$953,880
Mr. Utpal Koppikar (1971) Chief Financial Officer	54	$596,380
Mr. Joseph Newell (1970) Executive Vice President & Chief Operating Officer	55	$546,100
Eric Hyllengren Head of Investor Relations & Fin.
Mr. Amar Murugan Senior Vice President & Gen. Counsel
Mr. Steve Bertram Senior Vice President & Chief People Officer
Kerry Beth Daly Head of Corporation Communications
Dr. Manher Joshi Chief Medical Officer
Dr. José Eduardo Vidal Ph.D. Head of Quality Assurance and Process Sciences
Mr. Tim Valko Senior Vice President of Global Manufacturing & Supply Chain

Frequently Asked Questions (FAQ)

What's the price of Atara Biotherapeutics stock today?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $15.89.
When is Atara Biotherapeutics's next earnings date?

Unfortunately, Atara Biotherapeutics's (0HIY.L) next earnings date is currently unknown.
Does Atara Biotherapeutics pay dividends?

No, Atara Biotherapeutics does not pay dividends.
How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of 76.15M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 86.51% to 8.57M US dollars.
What is Atara Biotherapeutics's stock symbol?

Atara Biotherapeutics, Inc. is traded on the LSE under the ticker symbol "0HIY.L".
What is Atara Biotherapeutics's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Atara Biotherapeutics?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Atara Biotherapeutics's key executives?
Atara Biotherapeutics's management team includes the following people:
- Dr. Pascal Touchon D.V.M. Pres, Chief Executive Officer & Director(age: 62, pay: $953,880)
- Mr. Utpal Koppikar Chief Financial Officer(age: 54, pay: $596,380)
- Mr. Joseph Newell Executive Vice President & Chief Operating Officer(age: 55, pay: $546,100)
- Eric Hyllengren Head of Investor Relations & Fin.
- Mr. Amar Murugan Senior Vice President & Gen. Counsel
- Mr. Steve Bertram Senior Vice President & Chief People Officer
- Kerry Beth Daly Head of Corporation Communications
- Dr. Manher Joshi Chief Medical Officer
- Dr. José Eduardo Vidal Ph.D. Head of Quality Assurance and Process Sciences
- Mr. Tim Valko Senior Vice President of Global Manufacturing & Supply Chain
How many employees does Atara Biotherapeutics have?

As Jul 2024, Atara Biotherapeutics employs 173 workers, which is 48% less then previous quarter.
When Atara Biotherapeutics went public?

Atara Biotherapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
What is Atara Biotherapeutics's official website?

The official website for Atara Biotherapeutics is atarabio.com.
Where are Atara Biotherapeutics's headquarters?

Atara Biotherapeutics is headquartered at 611 Gateway Boulevard, South San Francisco, CA.
How can i contact Atara Biotherapeutics?

Atara Biotherapeutics's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 02788930.

Atara Biotherapeutics, Inc.

atarabio.com

Exchange:

LSE

Full time employees:

165

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

+65 02788930

611 Gateway Boulevard
South San Francisco, CA 94080

:
ISIN: US0465131078
: